Table 5.
Association of tumoral BRD4 expression with clinicopathologic parameters
| Characteristic | BRD4/low | % | BRD4/high | % | P-value** |
|---|---|---|---|---|---|
| (n = 143) | (n = 469) | ||||
| Number | Number | ||||
| Number of Recurrences | 16 | 11.2 | 68 | 14.5 | |
| Menopausal status | |||||
| Pre | 30 | 21.0 | 172 | 36.7 | 0.0018 |
| Peri | 6 | 4.2 | 22 | 4.7 | |
| Post | 106 | 74.1 | 274 | 58.4 | |
| ND‡ | 1 | 0.7 | 1 | 0.2 | |
| Lymphatic Invasion | |||||
| Yes | 19 | 13.3 | 56 | 12.0 | 0.6592 |
| No | 123 | 86.0 | 411 | 87.6 | |
| ND‡ | 1 | 0.7 | 2 | 0.4 | |
| Tumor Size | |||||
| < =0.5 cm | 3 | 2.1 | 6 | 1.3 | 0.0049 |
| > 0.5 to 1 cm | 26 | 18.2 | 37 | 7.9 | |
| > 1 to 2 cm | 64 | 44.8 | 213 | 45.4 | |
| > 2 to 5 cm | 45 | 31.5 | 193 | 41.2 | |
| > 5 cm | 4 | 2.8 | 19 | 4.1 | |
| ND‡ | 1 | 0.7 | 1 | 0.2 | |
| Estrogen receptor | |||||
| Positive | 87 | 60.8 | 302 | 64.4 | 0.1249 |
| Negative/Equivocal | 28 | 19.6 | 108 | 23.0 | |
| ND‡ | 28 | 19.6 | 59 | 12.6 | |
| Progesterone receptor | |||||
| Positive | 80 | 55.9 | 267 | 56.9 | 0.0935 |
| Negative/Equivocal | 35 | 24.5 | 143 | 30.5 | |
| ND‡ | 28 | 19.6 | 59 | 12.6 | |
| Histological grade | |||||
| 1a | 49 | 34.3 | 142 | 30.3 | 0.1497 |
| 2 | 53 | 37.1 | 157 | 33.5 | |
| 3 | 25 | 17.5 | 127 | 27.1 | |
| ND‡ | 16 | 11.2 | 43 | 9.2 | |
| Adjuvant treatment | |||||
| Hormonal | 70 | 49.0 | 193 | 41.2 | 0.2223 |
| Chemotherapy | 16 | 11.2 | 82 | 17.5 | |
| Both | 4 | 2.8 | 13 | 2.8 | |
| None | 52 | 36.4 | 180 | 38.4 | |
| ND‡ | 1 | 0.7 | 1 | 0.2 | |
| Age (years) | |||||
| Mean | 58.25 | 55.14 | |||
| SD | 10.13 | 11.86 | |||
| Minimum | 33.51 | 25.49 | |||
| Maximum | 73.82 | 75.82 | |||
‡Unknown, not done or missing
**Chi-square test; ND groups were not used in testing
aIncludes mucinous, lobular and tubular subtypes